- Company announcement
- Investor presentation
- Financial workbook
- Conference call webcast (04 August 2021, 19:00 CEST)
-
Conference call audio link (04 August 2021,
19:00 CEST)
- London webcast (06 August2021, 13:00 CEST)
- London earnings presentation audio link (06 August 2021, 13:00 CEST)
Conference call webcast (05 May 2021, 13:00 CET)
Conference call audio link (05 May 2021, 13:00 CET)
London webcast (06 May 2021, 13:00 CET)
London earnings presentation audio link (06 May 2021, 13:00 CET)
Silent period
1 October - 2 November
Q3 2021 financial results
3 November 2021
Silent period
1 January - 1 February 2022
Q4 2021 financial results release
2 February 2022
28 June: R&D investor call
07 June: Approval of Wegovy™ in the US
21 May: International Operations call
- Annual report 2020 (UK)
-
Company
announcement
- Novo Nordisk CEO reflects on the full year results (video)
- Investor presentation
-
Conference call webcast (03 February 2021,
13:00 CET)
- Conference call audio link (03 February 2021, 13:00 CET)
- London webcast (05 February 2021, 12:00 CET)
- London earnings presentation audio link (05 February 2021, 12:00 CET)
- Financial workbook
- Company Announcement
- Investor presentation
- Conference call webcast (30 Oct 2020, 13:00 CET)
- Conference call audio link (30 Oct 2020, 13:00 CET)
- London webcast (2 Nov 2020, 13:00 CET)
- London earnings presentation audio link (2 Nov 2020, 13:00 CET)
- Financial workbook
- Company announcement
- Investor presentation
- Conference call webcast (6 Aug 2020, 13:00 CET)
- Conference call audio link (6 Aug 2020, 13:00 CET)
- London webcast (7 Aug 2020, 13:00 CET)
- London earnings presentation audio link (7 Aug 2020, 13:00 CET)
- Financial workbook
- Company announcement
- Investor presentation
- Conference call
webcast (6 May 2020, 13:00 CET)
- Conference call audio link (6 May 2020, 13:00 CET)
- London webcast (7 May
2020, 13:00 CET)
- London earnings presentation audio link (7 May 2020, 13:00 CET)
- Financial workbook
16 December: Decision to enter phase 3 development in Alzheimer’s disease and GLP-1 R&D strategy update
30 November: ESG conference call
- Presentation (webcast)
-
ESG presentation (pdf)
- Introduction
- Circular for Zero followed by Q&A
- Defeat Diabetes and Sustainable Workplace followed by Q&A
- Governance structure followed by
Q&A
9 October: Novo Nordisk raises sales and operating profit outlook
for 2020
19 June: R&D investor presentation
26 March: Annual General Meeting
- Conference call webcast (5 February, 13:00 CET)
- London webcast (6 February, 14:15 CET)
- Conference call webcast (1 November, 13:00 CEST)
- London webcast (4 November, 14:15 CEST)
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Investors
Share price
{{priceData.date}} {{priceData.time}}
